Characterization of the ERAD process of the L444P mutant glucocerebrosidase variant

Blood Cells, Molecules, and Diseases

Volumn 46, Issue 1, 2011, Pages 4-10

  Bendikov Bar, Inna ^a   Ron, Idit ^a   Filocamo, Mirella ^b   Horowitz, Mia ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b G GASLINI INSTITUTE   (Italy)

Author keywords

Ambroxol; ERAD; Gaucher disease; Glucocerebrosidase

Indexed keywords

AMBROXOL; GLUCOSYLCERAMIDASE; PROTEASOME;

ARTICLE; CELL LINE; CONTROLLED STUDY; ENDOPLASMIC RETICULUM; ENZYME ACTIVITY; ENZYME STABILITY; GAUCHER DISEASE; GENE MUTATION; HOMOZYGOSITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; SKIN FIBROBLAST; UBIQUITINATION;

AMBROXOL; BLOTTING, WESTERN; CELLS, CULTURED; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENDOPLASMIC RETICULUM; FIBROBLASTS; GENETIC VARIATION; GLUCOSYLCERAMIDASE; HUMANS; MOLECULAR CHAPERONES; MUTATION; SKIN;

EID: 78650805237     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcmd.2010.10.012     Document Type: Article

References (35)

1. Beutler E., Grabowski G.A. Gaucher Disease. The Metabolic and Molecular Bases of Inherited Diseases 1995, 2641-2663. McGraw Hill. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
2. Bembi B., Zambito Marsala S., Sidransky E., Ciana G., Carrozzi M., Zorzon M., Martini C., Gioulis M., Pittis M.G., Capus L. Gaucher's disease with Parkinson's disease: clinical and pathological aspects. Neurology 2003, 61:99-101.
3. Neudorfer O., Giladi N., Elstein D., Abrahamov A., Turezkite T., Aghai E., Reches A., Bembi B., Zimran A. Occurrence of Parkinson's syndrome in type I Gaucher disease. QJM 1996, 89:691-694.
4. Tayebi N., Callahan M., Madike V., Stubblefield B.K., Orvisky E., Krasnewich D., Fillano J.J., Sidransky E. Gaucher disease and parkinsonism: a phenotypic and genotypic characterization. Mol. Genet. Metab. 2001, 73:313-321.
5. Tayebi N., Walker J., Stubblefield B., Orvisky E., LaMarca M.E., Wong K., Rosenbaum H., Schiffmann R., Bembi B., Sidransky E. Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism?. Mol. Genet. Metab. 2003, 79:104-109.
6. Erickson A.H., Ginns E.I., Barranger J.A. Biosynthesis of the lysosomal enzyme glucocerebrosidase. J. Biol. Chem. 1985, 260(26):14319-14324.
7. Kopito R.R. ER quality control: the cytoplasmic connection. Cell 1997, 88:427-430.
8. Ron I., Horowitz M. ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity. Hum. Mol. Genet. 2005, 14:2387-2398.
9. Beutler E., Gelbart T., Scott C.R. Hematologically important mutations: Gaucher disease. Blood Cells Mol. Dis. 2005, 35:355-364.
10. Goker-Alpan O. Optimal therapy in Gaucher disease. Ther Clin Risk Manag 2010, 6:315-323.
11. Mehta A., Beck M., Eyskens F., Feliciani C., Kantola I., Ramaswami U., Rolfs A., Rivera A., Waldek S., Germain D.P. Fabry disease: a review of current management strategies. QJM 2010, 103:641-659.
12. Lim-Melia E.R., Kronn D.F. Current enzyme replacement therapy for the treatment of lysosomal storage diseases. Pediatr. Ann. 2009, 38:448-455.
13. Grabowski G.A. Phenotype, diagnosis, and treatment of Gaucher's disease. Lancet 2008, 372:1263-1271.
14. Parenti G. Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics. EMBO Mol. Med. 2009, 1:268-279.
15. Tropak M.B., Blanchard J.E., Withers S.G., Brown E.D., Mahuran D. High-throughput screening for human lysosomal beta-N-Acetyl hexosaminidase inhibitors acting as pharmacological chaperones. Chem. Biol. 2007, 14:153-164.
16. Yu Z., Sawkar A.R., Kelly J.W. Pharmacologic chaperoning as a strategy to treat Gaucher disease. FEBS J. 2007, 274:4944-4950.
17. Khanna R., Benjamin E.R., Pellegrino L., Schilling A., Rigat B.A., Soska R., Nafar H., Ranes E., Feng J., Lun Y., Powe A.C., Palling D.J., Wustman B.A., Schiffmann R., Mahuran D.J., Lockhart D.J., Valenzano K.J. The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of beta-glucosidase. FEBS J. 2010, 277:1618-1638.
18. Maegawa G.H., Tropak M.B., Buttner J.D., Rigat B.A., Fuller M., Pandit D., Tang L., Kornhaber G.J., Hamuro Y., Clarke J.T., Mahuran D.J. Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease. J. Biol. Chem. 2009, 284:23502-23516.
19. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
20. Hershko A., Eytan E., Ciechanover A., Haas A.L. Immunochemical analysis of the turnover of ubiquitin-protein conjugates in intact cells. Relationship to the breakdown of abnormal proteins. J. Biol. Chem. 1982, 257:13964-13970.
21. Maley F., Trimble R.B., Tarentino A.L., Plummer T.H. Characterization of glycoproteins and their associated oligosaccharides through the use of endoglycosidases. Anal. Biochem. 1989, 180:195-204.
22. Plummer T.H., Elder J.H., Alexander S., Phelan A.W., Tarentino A.L. Demonstration of peptide:N-glycosidase F activity in endo-beta-N-acetylglucosaminidase F preparations. J. Biol. Chem. 1984, 259:10700-10704.
23. Trimble R.B., Tarentino A.L. Identification of distinct endoglycosidase (endo) activities in Flavobacterium meningosepticum: endo F1, endo F2, and endo F3. Endo F1 and endo H hydrolyze only high mannose and hybrid glycans. J. Biol. Chem. 1991, 266:1646-1651.
24. Maki C.G., Huibregtse J.M., Howley P.M. In vivo ubiquitination and proteasome-mediated degradation of p53(1). Cancer Res. 1996, 56:2649-2654.
25. Obrig T.G., Culp W.J., McKeehan W.L., Hardesty B. The mechanism by which cycloheximide and related glutarimide antibiotics inhibit peptide synthesis on reticulocyte ribosomes. J. Biol. Chem. 1971, 246:174-181.
26. Ron I., Horowitz M. Intracellular cholesterol modifies the ERAD of glucocerebrosidase in Gaucher disease patients. Mol. Genet. Metab. 2008, 93:426-436.
27. Perlmutter D.H. Chemical chaperones: a pharmacological strategy for disorders of protein folding and trafficking. Pediatr. Res. 2002, 52:832-836.
28. Schueler U.H., Kolter T., Kaneski C.R., Zirzow G.C., Sandhoff K., Brady R.O. Correlation between enzyme activity and substrate storage in a cell culture model system for Gaucher disease. J. Inherit. Metab. Dis. 2004, 27:649-658.
29. Asano N., Ishii S., Kizu H., Ikeda K., Yasuda K., Kato A., Martin O.R., Fan J.Q. In vitro inhibition and intracellular enhancement of lysosomal alpha-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives. Eur. J. Biochem. 2000, 267:4179-4186.
30. Matsuda J., Suzuki O., Oshima A., Yamamoto Y., Noguchi A., Takimoto K., Itoh M., Matsuzaki Y., Yasuda Y., Ogawa S., Sakata Y., Nanba E., Higaki K., Ogawa Y., Tominaga L., Ohno K., Iwasaki H., Watanabe H., Brady R.O., Suzuki Y. Chemical chaperone therapy for brain pathology in G(M1)-gangliosidosis. Proc. Natl Acad. Sci. USA 2003, 100:15912-15917.
31. Maegawa G.H., Tropak M., Buttner J., Stockley T., Kok F., Clarke J.T., Mahuran D.J. Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis. J. Biol. Chem. 2007, 282:9150-9161.
32. Parenti G., Zuppaldi A., Gabriela Pittis M., Rosaria Tuzzi M., Annunziata I., Meroni G., Porto C., Donaudy F., Rossi B., Rossi M., Filocamo M., Donati A., Bembi B., Ballabio A., Andria G. Pharmacological enhancement of mutated alpha-glucosidase activity in fibroblasts from patients with Pompe disease. Mol. Ther. 2007, 15:508-514.
33. Sawkar A.R., Cheng W.C., Beutler E., Wong C.H., Balch W.E., Kelly J.W. Chemical chaperones increase the cellular activity of N370S beta -glucosidase: a therapeutic strategy for Gaucher disease. Proc. Natl Acad. Sci. USA 2002, 99:15428-15433.
34. Lin H., Sugimoto Y., Ohsaki Y., Ninomiya H., Oka A., Taniguchi M., Ida H., Eto Y., Ogawa S., Matsuzaki Y., Sawa M., Inoue T., Higaki K., Nanba E., Ohno K., Suzuki Y. N-octyl-beta-valienamine up-regulates activity of F213I mutant beta-glucosidase in cultured cells: a potential chemical chaperone therapy for Gaucher disease. Biochim. Biophys. Acta 2004, 1689:219-228.
35. Sawkar A.R., Adamski-Werner S.L., Cheng W.C., Wong C.H., Beutler E., Zimmer K.P., Kelly J.W. Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles. Chem. Biol. 2005, 12:1235-1244.